Inventiva, a clinical-stage biopharmaceutical company, announced the total number of shares and voting rights as of May 22, 2026. The company has 209,007,475 shares outstanding with 218,082,368 total voting rights, both gross and net. This disclosure is in line with regulatory requirements and is important for shareholders ahead of the general meeting scheduled for June 30, 2026. Inventiva is developing a treatment for NASH with its drug lanifibranor currently in phase 3 trials.
Inventiva, a biopharmaceutical company, announced the details for its Annual General Meeting (AGM) on June 30, 2026, where shareholders will vote on a key resolution involving a master agreement with the European Investment Bank (EIB). This agreement...
Inventiva, a clinical-stage biopharmaceutical company, announced the total number of shares and voting rights as of May 22, 2026. The company reported 209,007,475 shares outstanding with 218,082,368 total voting rights, both gross and net. This discl...
Inventiva announced the availability of documents for its Combined General Meeting on June 30, 2026, where shareholders will vote on key resolutions including the repayment of loans to the European Investment Bank (EIB) and the buyback and cancellati...
SpaceX is set to go public with an expected valuation around $1.75 trillion, potentially the largest IPO ever. Investor Ron Baron predicts the company could be worth up to $30 trillion in 10-15 years, but a Benzinga poll finds 61% of viewers believe ...
Bank of America predicts the 2026 World Cup, hosted partly in the US, will increase beer and soft drink consumption, creating a temporary sales boost for beverage companies. Using data from the 1994 US-hosted World Cup, BofA expects about 0.8 million...
